Identification of factors involved in the anti-tumor activity of carnosine on glioblastomas using a proteomics approach

Cancer Investigation

Volumn 29, Issue 4, 2011, Pages 272-281

  Asperger, Ansgar ^a   Renner, Christof ^a   Menzel, Mandy ^a   Gebhardt, Rolf ^b   Meixensberger, JÜrgen ^a   Gaunitz, Frank ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Brain tumors; Therapy; Treatment; Tumor cell biology

Indexed keywords

BCL2 ASSOCIATED ATHANOGENE 2; BINDING PROTEIN; CARNOSINE; HYPOXIA INDUCIBLE FACTOR 1; UNCLASSIFIED DRUG; VON HIPPEL LINDAU BINDING PROTEIN 1;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CLINICAL ARTICLE; FACTORIAL ANALYSIS; FEMALE; FRONTAL LOBE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OCCIPITAL LOBE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN ISOLATION; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR LOCALIZATION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARNOSINE; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MIDDLE AGED; MOLECULAR CHAPERONES; NEOPLASM PROTEINS; PEPTIDE MAPPING; PROTEIN FOLDING; PROTEOMICS; RNA, MESSENGER; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR CELLS, CULTURED;

EID: 79953776900     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.550666     Document Type: Article

References (52)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 2007;114:97-109. (Pubitemid 47103521)
2. Brown M, Schrot R, Bauer K, LeTendre D. Incidence of first primary central nervous system tumors in California, 2001-2005. J Neuro-Oncol 2009;94:249-261.
3. Sarin H. Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. J Transl Med 2009;7:77.
4. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996. (Pubitemid 40349501)
5. Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, Lillehei KO, Bernstein M, Brem H, Sloan A, BergerMS, Chang S. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003;99:467-473. (Pubitemid 37040405)
6. Bansal K, Liang ML, Rutka JT. Molecular biology of human gliomas. Technol Cancer Res Treat 2006;5:185-194. (Pubitemid 43946252)
7. Renner C, Seyffarth A, de Arriba S, Meixensberger J, Gebhardt R, Gaunitz F. Carnosine inhibits growth of cells isolated from human glioblastoma multiforme. Int J Pept Res Ther 2008;14:127-135. (Pubitemid 351678728)
8. Renner C, Zemitzsch N, Fuchs B, Geiger KD, Hermes M, Hengstler J, Gebhardt R, Meixensberger J, Gaunitz F. Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model. Mol Cancer 2010;9:2.
9. Gulewitsch W, Amiradzibi S. Ueber das Carnosin; eine neue organische Base des Fleischextraktes. Ber Deut Chem Ges 1900; 33:1902-1903.
10. Mannion AF, Jakeman PM, Dunnett M, Harris RC, Willan PL. Carnosine and anserine concentrations in the quadriceps femoris muscle of healthy humans. Eur J Appl Physiol Occup Physiol 1992;64:47-50.
11. Boldyrev AA. Problems and perspectives in studying the biological role of carnosine. Biochemistry (Mosc) 2000;65:751-756.
12. Guiotto A, Calderan A, Ruzza P, Borin G. Carnosine and carnosine-related antioxidants: a review. Curr Med Chem 2005;12:2293-2315. (Pubitemid 41300782)
13. Smith EC. The buffering of muscle in rigor; protein, phosphate and carnosine. J Physiol 1938;92:336-343.
14. Baran EJ. Metal complexes of carnosine. Biochemistry (Mosc) 2000;65:789-797.
15. Nadi NS,Hirsch JD,Margolis FL. Laminar distribution of putative neurotransmitter amino acids and ligand binding sites in the dog olfactory bulb. J Neurochem 1980;34:138-146. (Pubitemid 10172689)
16. Kohen R, Yamamoto Y, CundyKC,Ames BN. Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. Proc Natl Acad Sci U S A 1988;85:3175-3179.
17. Gallant S, Semyonova M, Yuneva M. Carnosine as a potential antisenescence drug. Biochemistry (Mosc) 2000;65:866-868.
18. Boldyrev A, Song R, Lawrence D, Carpenter DO. Carnosine protects against excitotoxic cell death independently of effects on reactive oxygen species. Neuroscience 1999;94:571-577. (Pubitemid 29436082)
19. Reddy VP, Garrett MR, Perry G, Smith MA. Carnosine: a versatile antioxidant and antiglycating agent. Sci Aging Knowledge Environ 2005;18:e12.
20. Renner C, Asperger A, Seyffarth A, Meixensberger J, Gebhardt R, Gaunitz F. Carnosine inhibits ATP production in cells from malignant glioma. Neurol Res 2010;32:101-105.
21. Severina IS, Bussygina OG, Pyatakova NV. Carnosine as a regulator of soluble guanylate cyclase. Biochemistry (Mosc) 2000;65:783-788.
22. Ito-Kato E, Suzuki N, Maeno M, Takada T, Tanabe N, Takayama T, Ito K, Otsuka K. Effect of carnosine on runt-related transcription factor-2/core binding factor alpha-1 and Sox9 expressions of human periodontal ligament cells. J Periodontal Res 2004;39:199-204. (Pubitemid 38692089)
23. Blum H, Beier H, Gross HJ. Improved silver staining of plantproteins, RNA and DNA in polyacrylamide gels. Electrophoresis 1987;8:93-99.
24. Mortz E, Krogh TN, VorumH, Gorg A. Improved silver staining protocols for high sensitivity protein identification using matrixassisted laser desorption/ionization-time of flight analysis. Proteomics 2001;1:1359-1363. (Pubitemid 33587891)
25. Pruitt KD, Tatusova T, Maglott DR. NCBI reference sequences (Ref Seq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res 2007;35:D61-D65. (Pubitemid 46056171)
26. Stupp R, Hegi ME, Mason WP, Van Den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J,Marosi C, Vecht CJ,Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-466.
27. Fountoulakis M. Application of proteomics technologies in the investigation of the brain. Mass Spectrom Rev 2004;23:231-258.
28. Badenas C, To-Figueras J, Phillips JD, Warby CA, Munoz C, Herrero C. Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relatives. Clin Genet 2009;75:346-353.
29. Navone NM, Polo CF, Frisardi AL, Andrade NE, Battle AM. DEL C. Heme Biosynthesis in human breast cancer-mimetic in vitro studies and some heme enzymic activity levels. Int J Biochem 1990;22:1407-1411. (Pubitemid 20370322)
30. Vargas PD, Furuyama K, Sassa S, Shibahara S. Hypoxia decreases the expression of the two enzymes responsible for producing linear and cyclic tetrapyrroles in the heme biosynthetic pathway. FEBS J 2008;275:5947-5959.
31. Samland AK, Sprenger GA. Transaldolase: from biochemistry to human disease. Int J Biochem Cell 2009;41:1482-1494.
32. Wamelink M, Struys E, Jakobs C. The biochemistry, metabolism and inherited defects of the pentose phosphate pathway: a review. J Inherit Metab Dis 2008;31:703-717.
33. Ramos-Montoya A, Lee WNP, Bassilian S, Lim S, Trebukhina RV, Kazhyna MV, Ciudad CJ, Noe V, Centelles JJ, Cascante M. Pentose phosphate cycle oxidative and nonoxidative balance: a new vulnerable target for overcoming drug resistance in cancer. Int J Cancer 2006;119:2733-2741. (Pubitemid 44846223)
34. Kira Y, Nishikawa M.The identification and characterization of a new GTP-binding protein (Gbp45) involved in cell proliferation and death related to mitochondrial function. Cell Mol Biol Lett 2008;13:570-584.
35. Koller-Eichhorn R, Marquardt T, Gail R, Wittinghofer A, Kostrewa D, Kutay U, Kambach C.Human OLA1 defines an ATPase subfamily in the Obg family of GTP-binding proteins. J Biol Chem 2007;282:19928-19937. (Pubitemid 47100072)
36. Zhang J, Rubio V, Lieberman MW, Shi ZZ. OLA1, an Obg-like ATPase, suppresses antioxidant response via nontranscriptional mechanisms. Proc Natl Acad Sci U S A 2009;106:15356-15361.
37. Zhang JW, Rubio V, Zheng S, Shi ZZ. Knockdown ofOLA1, a regulator of oxidative stress response, inhibits motility and invasion of breast cancer cells. J Zhejiang Univ-Sci B 2009;10:796-804.
38. Borges JC, Fischer H, Craievich AF,Hansen LD, Ramos CHI. Free human mitochondrial GrpE is a symmetric dimer in solution. J Biol Chem 2003;278:35337-35344. (Pubitemid 37102302)
39. ShermanM, MulthoffG.Heat shock proteins in cancer.Ann N Acad Sci 2007;1113:192-201. (Pubitemid 350015025)
40. Graner MW, Raynes DA, Bigner DD, Guerriero V. Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfaces. Cancer Sci 2009;100:1870-1879.
41. Takayama S, Xie ZH, Reed JC. An evolutionarily conserved family of Hsp70/Hsc70 molecular chaperone regulators. J Biol Chem 1999;274:781-786.
42. Ueda K, Kosako H, Fukui Y, Hattori S. Proteomic identification of Bcl2-associated athanogene 2 as a novel MAPK-activated protein kinase 2 substrate. J Biol Chem 2004;279:41815-41821. (Pubitemid 39313629)
43. 43Arndt V, Daniel C, Nastainczyk W, Alberti S, Hohfeld J. BAG-2 acts as an inhibitor of the chaperone-associated ubiquitin ligase CHIP. Mol Biol Cell 2005;16:5891-5900. (Pubitemid 41752235)
44. Dai Q, Qian SB, Li HH, McDonough H, Borchers C, Huang D, Takayama S, Younger JM, Ren HY, Cyr DM, Patterson C. Regulation of the cytoplasmic quality control protein degradation pathway by BAG2. J Biol Chem 2005;280:38673-38681. (Pubitemid 43853770)
45. LuoW, Zhong J, Chang R, Hu H, Pandey A, Semenza GL. HSP70 and CHIP selectively mediate ubiquitination and degradation of hypoxia-incucible factor (HIF)-1α but not HIF-2α. J Bol Chem 2009;582:3663-1563.
46. Hohfeld J, Jentsch S. GrpE-like regulation of the Hsc70 chaperone by the anti-apoptotic protein BAG-1. Embo J 1997;16:6209-6216. (Pubitemid 27458341)
47. Tsuchiya H, Iseda T, Hino O. Identification of a novel protein (VBP-1) binding to the vonHippel-Lindau (VHL) tumor suppressor gene product. Cancer Res 1996;56:2881-2885.
48. Mole DR, Ratcliffe PJ. Cellular oxygen sensing in health and disease. Ped Nephrol 2008;23:681-694. (Pubitemid 351486180)
49. Sun X, Liu M, Wei Y, Liu F, Zhi X, Xu R, Krissansen GW. Overexpression of von Hippel-Lindau tumor suppressor protein and antisense HIF-1 alpha eradicates gliomas. Cancer Gene Ther 2006;13:428-435.
50. Hervouet E, Cizkova A, Demont J, Vojtiskova A, Pecina P, Hal NLWF, Keijer J, Simonnet H, Ivanek R, Kmoch S, Godinot C, Houstek J. HIF and reactive oxygen species regulate oxidative phosphorylation in cancer. Carcinogenesis 2008;29:1528-1537.
51. Warburg O, Posener K, Negelein E. Ueber den Stoffwechsel der Carcinomzelle. Biochem Z 1924;152:309-344.
52. Bharadwaj LA, Davies GF, Xavier IJ, Ovsenek N. L-carnosine and verapamil inhibit hypoxia-induced expression of hypoxia inducible factor (HIF-1 alpha) in H9c2 cardiomyoblasts. Pharmacol Res 2002;45:175-181. (Pubitemid 35418358)